Evaluation of Nutlin-3 and other MDM2-p53 antagonists in preclinical models of neuroblastoma have reported potent anti-tumor effects such as induction of growth arrest, senescence, differentiation and apoptosis, and inhibition of tumor cell proliferation and metastasis (Barbieri et al., 2006; Van Maerken et al., 2006, 2009a, 2011; Hardcastle et al., 2011; Patterson et al., 2011; Gamble et al., 2012). The gene discussed is MDM2; the disease is neoplasm.